Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model

To evaluate the therapeutic effects of topical RCI001 (RCI) and compare its efficacy with that of 1% prednisolone acetate (PDE) and 5% Lifitegrast in a modified mixed dry eye disease (DED) model. The environmental DED model was induced in BALB/c mice in a dry chamber with scopolamine. The eyes of th...

Full description

Saved in:
Bibliographic Details
Published in:Eye and vision (Novato, Calif.) Calif.), 2024-06, Vol.11 (1), p.19-11, Article 19
Main Authors: Jung, Young-Ho, Ku, Young Ah, Moon, Jayoon, Kim, Seunghoon, Ryu, Jin Suk, Yoon, Chang Ho, Chung, Myung Hee, Kim, Yong Ho, Kim, Mee Kum, Kim, Dong Hyun
Format: Article
Language:English
Subjects:
Acetates
Analysis
B cells
Corticosteroids
Cytokines
Dry eye disease
Eye diseases
Fluorescent antibody technique
Health aspects
Immunofluorescence
Inflammation
Oxidative stress
Phosphates
Prednisolone
RCI001
Therapeutics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the therapeutic effects of topical RCI001 (RCI) and compare its efficacy with that of 1% prednisolone acetate (PDE) and 5% Lifitegrast in a modified mixed dry eye disease (DED) model. The environmental DED model was induced in BALB/c mice in a dry chamber with scopolamine. The eyes of the mice were treated topically with phosphate buffered saline (PBS), PDE, Lifitegrast or RCI twice daily for 1 week. Ocular surface staining (OSS), tear secretion, inflammatory cytokines in the ocular surface and lacrimal gland, and immunofluorescence staining in the conjunctiva and cornea(CC) were assessed. The RCI group demonstrated better improvement of OSS and tear secretion than the PBS group (OSS, PBS: 13.0 ± 1.6, RCI: 9.4 ± 3.0; tear secretion, PBS: 5.0 ± 0.4 mm, RCI: 7.0 ± 0.3 mm, each P 
ISSN:2326-0254
2326-0254
DOI:10.1186/s40662-024-00388-z